Royalty Pharma plc RPRX

Key data

What the scoreboard pays for

There is no annual bonus here, and no named officer received one in 2025 or 2024. Everything else runs through one instrument, and a fifth of the profit on each two-year batch belongs to Legorreta's entities for the life of those royalties. He allocates the slices among the executives himself, consulting the compensation committee rather than answering to it. The annual report says the arrangement may create an incentive to make riskier or more speculative acquisitions.

What it has paid so far

The 2024 proxy told shareholders not to expect a material award until the second half of this decade. The first payment landed in the first quarter of 2025. None of the three tests changed, so what moved was the forecast running through them, and that forecast is management's own. Of the $81.2 million earned in 2025, $38.4 million was the founder's retained share and $20.9 million reduced a liability the internalization created at $422.5 million.

The old structure paid the manager 6.5% of cash receipts. When the company sold its MorphoSys funding bonds for roughly $511 million in January 2025, $33.2 million reached Legorreta as manager profit, a computed 6.5% of a receipt that portfolio receipts itself excludes as an asset sale. That fee is gone. What replaced it is a claim on profit rather than gross cash, which is the better structure for an owner and the larger number for him.

Where it stands and what he does next

The fourth portfolio opened January 1, 2026 and closes December 31, 2027. Every dollar deployed inside that window starts a new pool he takes a fifth of. Nothing spent on repurchases or dividends does, and the first half shows which way the money went.

Capital is not what holds him back. Debt sat unchanged at $9.2B against $3.0B of 2025 adjusted earnings, a computed 3.1 times against a covenant ceiling of 4.00, with $812.0 million of cash at June 30 and $1.8B of repurchase authority left at the year end, running through June 2027. The constraint is supply, and the 10-K states it plainly: the company may not find enough royalties to invest the capital available at its targeted rate. Pressure of that shape lands on price and on the risk curve. Three lines show it. Development-stage funding, where the speculative end lives. The repurchase line, now the clearest read on whether capital is being pushed toward the carry. And announced value against cash actually out the door, $1.7B against $1.1B as of August 4.

Legorreta sold nothing in the twelve months to September 16, 2026. He acquired 403,424 shares in four tranches dated to quarterly settlement and gifted 30,000 partnership interests. The four executives below him disposed of 1,934,543 shares under code S for a computed $86.3 million between $38.28 and $59.97, each running accounts to zero. The man whose fifth is still unearned is the one who did not sell.

Closing thoughts

Royalty Pharma pays its chief executive a fifth of the profit on the royalties it buys and nothing at all for the share price, the dividend or the repurchase. The plan wants deployment, and the first half of 2026 delivered it by starving the repurchase down to $94.7 million. What the fourth portfolio will reveal is what he had to pay to find the deals.